Chengdu Kanghua Biological Products Co., Ltd. (300841.SZ)
CNY 54.39
(-1.2%)
CNY 54.39
(-1.2%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 640.61 Million CNY | -13.89% |
| 2022 | 728.08 Million CNY | -19.45% |
| 2021 | 937.52 Million CNY | 89.95% |
| 2020 | 496.42 Million CNY | 108.97% |
| 2019 | 233.86 Million CNY | 7.18% |
| 2018 | 199.22 Million CNY | 99.05% |
| 2017 | 105.73 Million CNY | 192.29% |
| 2016 | 26.37 Million CNY | -2.75% |
| 2015 | 34.75 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | 112.43 Million CNY | -45.08% |
| 2024 Q1 | 178.49 Million CNY | -20.85% |
| 2024 Q2 | 203.21 Million CNY | 14.69% |
| 2023 Q4 | 225.5 Million CNY | 97.05% |
| 2023 FY | - CNY | -13.89% |
| 2023 Q1 | 112.65 Million CNY | -35.13% |
| 2023 Q2 | 179.51 Million CNY | 59.35% |
| 2023 Q3 | 114.44 Million CNY | -36.25% |
| 2022 Q4 | 173.66 Million CNY | -2.58% |
| 2022 FY | - CNY | -19.45% |
| 2022 Q2 | 235.06 Million CNY | 59.01% |
| 2022 Q1 | 147.83 Million CNY | -71.38% |
| 2022 Q3 | 178.25 Million CNY | -24.17% |
| 2021 Q1 | 118.1 Million CNY | 42.85% |
| 2021 Q4 | 516.44 Million CNY | 331.72% |
| 2021 FY | - CNY | 89.95% |
| 2021 Q3 | 119.62 Million CNY | -34.28% |
| 2021 Q2 | 182.01 Million CNY | 54.12% |
| 2020 Q1 | 76.85 Million CNY | -36.35% |
| 2020 FY | - CNY | 108.97% |
| 2020 Q2 | 142.63 Million CNY | 85.6% |
| 2020 Q3 | 183.29 Million CNY | 28.5% |
| 2020 Q4 | 82.67 Million CNY | -54.89% |
| 2019 Q3 | 5.19 Million CNY | -91.48% |
| 2019 FY | - CNY | 7.18% |
| 2019 Q4 | 120.75 Million CNY | 2222.32% |
| 2019 Q2 | 61.04 Million CNY | 38.93% |
| 2019 Q1 | 43.93 Million CNY | -0.1% |
| 2018 Q4 | 43.98 Million CNY | 0.0% |
| 2018 FY | - CNY | 99.05% |
| 2017 FY | - CNY | 192.29% |
| 2016 FY | - CNY | -2.75% |
| 2015 FY | - CNY | 0.0% |